GUILFORD, Conn., March 24, 2018 -- Butterfly Network Inc. announced today that it has developed a novel augmented reality telemedicine technology on Butterly iQ™, the world’s first whole-body ultrasound imager. Butterfly iQ is a personal ultrasound device and sells for less than $2,000. Using Butterfly Tele-Guidance™ technology, an ultrasound expert can remotely guide any user to acquire even the most challenging ultrasound scans, bringing medical expertise to wherever it’s needed most. Only a fraction of the 40 million healthcare workers worldwide have the expertise to capture and interpret ultrasound images. Butterfly Tele-Guidance will expand their reach and facilitate early diagnosis and preventive medicine.
“This is an important step in fulfilling the promise of bringing ultrasound to the millions that do not have access to this essential medical technology,” said founder and serial entrepreneur Dr. Jonathan M. Rothberg. “I set out to democratize ultrasound imaging as I did with DNA sequencing. Two-thirds of the world has no access to medical imaging, and even in the developed world, expense and lack of expertise limit its accessibility. We solved the expense hurdle with the Butterfly iQ, and now with Butterfly Tele-Guidance technology, we are providing a unique approach to solving the expertise shortage.”
Butterfly Network conquered the problem of affordability of ultrasound systems by leveraging semiconductor technology and replacing the piezoelectric crystals with the world’s first commercial Ultrasound-on-a Chip™. Butterfly iQ received FDA clearance for 13 indications, the broadest ever for a single ultrasound probe, making it the only whole-body ultrasound imager. Priced at under $2k, the iQ also is the first personal ultrasound device, paving the way for all healthcare professionals to have a window into the body.
Butterfly Tele-Guidance is currently available for investigational and educational use only. Learn more at www.butterflynetwork.com.
ABOUT
Butterfly Network is a health technology company dedicated to democratizing medical imaging. Using a full-stack engineering approach combining hardware and software, Butterfly introduces the era of personal ultrasound with iQTM, the world’s first whole-body ultrasound system. Uniting a unique Transducer-on-CMOS technology with AI and the cloud, Butterfly iQ brings consumer-level ease of use and affordable imaging to the millions of healthcare practitioners without access. Butterfly Network invented and introduced the first FDA-cleared personal ultrasound device using ultrasound-on-a-chip™ technology. Butterfly has offices in NYC, Palo Alto and Guilford, Connecticut and is a member of the 4Catalyzer life sciences incubator, founded by Dr. Jonathan M. Rothberg, best known for inventing next-generation DNA sequencing, the technology underlying the $1,000 genome and the precision medical revolution.
CONTACT:
Wes Conard
[email protected]
415 385-4455
https://www.butterflynetwork.com/


Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 



